Innovent Biologics teams with Takeda on global IO therapies

Innovent Biologics and Takeda are teaming up. This global partnership seeks to accelerate the development and launch of Innovent’s new immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies. The partnership aims to provide groundbreaking cancer treatments to patients everywhere. It uses the combined skills of both companies.

The collaboration highlights three main investigational therapies from Innovent’s IO+ADC pipeline. IBI363 is a first-in-class bispecific antibody fusion protein that targets PD-1 and IL-2α. It shows strong anti-tumor effects. It’s a hopeful new therapy for immuno-oncology. IBI363 is now in global Phase 3 development. It targets second-line squamous non-small cell lung cancer (sqNSCLC). It has received Breakthrough Designation from China’s NMPA and Fast Track Designation from the U.S. FDA. Innovent and Takeda will work together to develop IBI363 globally. They will split the development costs and market it together in the U.S. Takeda will manage sales outside Greater China and the U.S.

IBI343 is an ADC that targets CLDN18.2. It is currently in Phase 3 trials for gastric and gastroesophageal cancers. So far, it shows promising safety and effectiveness. Innovent will grant Takeda exclusive global rights for development, manufacturing, and sales. This excludes Greater China. The companies aim to use IBI343 as a first-line treatment for gastric and pancreatic cancer.

Also Read: A.D.A.M. Partners with SOPHiA for Liquid Biopsy Japan

IBI3001, a first-in-class bispecific ADC targeting EGFR and B7-H3, is currently in Phase 1 trials. Takeda can choose to acquire exclusive global rights outside Greater China. If they do, this includes rights for development, manufacturing, and commercialization.

The partnership’s financial structure features an upfront payment of US$1.2 billion from Takeda to Innovent. This includes a US$100 million equity investment in Innovent. Innovent can receive up to US$10.2 billion in milestone payments for three therapies. This makes the total potential deal worth about US$11.4 billion. Innovent Biologics will also earn tiered royalties for each therapy outside Greater China. In the U.S., there’s a profit-sharing deal for IBI363.

This collaboration helps both companies boost the global reach of Innovent’s IO and ADC pipeline. It brings new treatment options to patients with great needs in oncology. It also boosts their commitment to improve precision cancer care around the globe.